SB

Sangui Biotech International IncMUN Sangui Stock Report

Last reporting period 31 Mar, 2023

Updated 11 Nov, 2024

Last price

Market cap $B

0

Micro

Exchange

XMUN - Boerse Muenchen

SBH.MU Stock Analysis

SB

Uncovered

Sangui Biotech International Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-67/100

Low score

Market cap $B

0

Dividend yield

Shares outstanding

209.9 B

Sangui BioTech International, Inc. is a holding company, which engages in the research, development, manufacture, and sale of medical and cosmetic products. The company is headquartered in Hamburg, Hamburg. The firm develops its products through its German subsidiary, SanguiBioTech AG (Sangui GmbH). The company is engaged in seeking to market and selling its products through partnerships with industry partners across the world. The company focuses on the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes. The company focuses its development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. The company offers external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin.

View Section: Eyestock Rating